Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Possible pathogenic mechanisms in inflammatory myopathies.

Ingrid E Lundberg1, Maryam Dastmalchi

  • 1Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska Hospital, SE-171 76, Stockholm, Sweden. ingrid.lundberg@medks.ki.se

Rheumatic Diseases Clinics of North America
|January 1, 2003
PubMed
Summary

Investigating idiopathic inflammatory myopathies (IIM) requires addressing research limitations. Understanding diverse disease mechanisms, including immune responses and metabolic changes, is crucial for developing targeted therapies for myositis patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-disease blood protein profiles of rheumatic autoimmune diseases.

Communications medicine·2026
Same author

Identification of Novel Risk Loci for Common B-Cell Lymphoma Subtypes Through Cross-Trait Analysis with Idiopathic Inflammatory Myopathies.

Cancers·2026
Same author

Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies.

Arthritis research & therapy·2026
Same author

Risk of second primary cancer and death in patients with idiopathic inflammatory myopathies.

Seminars in arthritis and rheumatism·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Correction to: Cardiac involvement in newly diagnosed patients with idiopathic inflammatory myopathies is associated with skeletal muscle involvement.

Clinical and experimental rheumatology·2026

Area of Science:

  • Rheumatology and Immunology
  • Muscle Diseases
  • Pathogenesis of Inflammatory Myopathies

Background:

  • Current research on idiopathic inflammatory myopathies (IIM) faces limitations due to patient selection bias and heterogeneity.
  • Incomplete understanding of disease mechanisms hinders the development of effective treatments for myositis.
  • Existing studies often overlook patients without inflammatory infiltrates and lack follow-up biopsies.

Purpose of the Study:

  • To highlight the limitations in current research approaches for understanding myositis pathogenesis.
  • To emphasize the need for comprehensive studies considering patient heterogeneity and diverse pathogenic mechanisms.
  • To identify potential therapeutic targets for improving outcomes in idiopathic inflammatory myopathies.

Main Methods:

Related Experiment Videos

  • Review of existing literature on idiopathic inflammatory myopathies (IIM) and their pathogenesis.
  • Analysis of limitations in patient selection, classification criteria, and study designs.
  • Discussion of cellular and humoral immune responses, metabolic disturbances, and cytokine involvement.

Main Results:

  • Research limitations include selection bias from focusing on inflammatory infiltrates and patient heterogeneity.
  • Current studies lack sufficient data on patients without inflammation and long-term treatment effects.
  • Both cellular and humoral immune responses are implicated, but a muscle-specific immune response remains unconfirmed.

Conclusions:

  • A deeper understanding of myositis pathogenesis requires addressing research limitations and considering diverse mechanisms.
  • Metabolic disturbances and cytokine dysregulation likely contribute to muscle weakness in IIM.
  • Targeting molecules like IL-1 and TNF-alpha presents a promising avenue for developing improved therapies.